```html

Kawasaki‑like Multisystem Inflammatory Syndrome in Children (MIS‑C)

Overview

Multisystem Inflammatory Syndrome in Children (MIS‑C) is a rare but severe condition that appears 2‑6 weeks after exposure to the virus that causes COVID‑19 (SARS‑CoV‑2). The syndrome shares many clinical features with Kawasaki disease—fever, rash, conjunctival injection, and coronary artery inflammation—hence it is often described as “Kawasaki‑like.”

• Who it affects: Primarily children and adolescents 0–19 years old, with the highest incidence in those 5‑12 years old. While Kawasaki disease is most common in children <5 years, MIS‑C disproportionately affects older children and teenagers.
• Prevalence: As of early 2024, the CDC reports an average of 1–2 MIS‑C cases per 100,000 persons under 21 years in the United States, with peaks following large COVID‑19 surges. Worldwide estimates range from 0.5‑2 per 100,000, varying by region and SARS‑CoV‑2 variant.
• Why it matters: If untreated, MIS‑C can cause rapid cardiac damage, shock, and organ failure. Early recognition and treatment dramatically improve outcomes (mortality <2 % in high‑resource settings).<sup>[1][2]</sup>

Symptoms

Symptoms usually develop 2‑6 weeks after a COVID‑19 infection (or known exposure) and involve at least two organ systems. The fever is almost always present.

System	Common Manifestations
Constitutional	Fever ≥38.0 °C lasting ≥24 h; fatigue; headache; myalgias; abdominal pain.
Cardiovascular	Chest pain; palpitations; hypotension; tachycardia; myocarditis; decreased left‑ventricular function; coronary artery dilation/aneurysm; arrhythmias; shock.
Gastrointestinal	Vomiting, diarrhea, abdominal pain, persistent nausea, hepatomegaly, elevated liver enzymes.
Dermatologic	Polymorphous rash (maculopapular, erythematous, or targetoid); erythema of palms/soles; “strawberry” tongue; cracked lips; conjunctival injection without discharge.
Neurologic	Headache, altered mental status, irritability, seizures (rare), meningismus.
Respiratory	Dyspnea, cough, hypoxia—often milder than acute COVID‑19 pneumonia but can coexist.
Renal/Genitourinary	Acute kidney injury, oliguria, proteinuria.

Children may present with a “Kawasaki‑like” phenotype (mucocutaneous changes, coronary involvement) or a more “shock‑type” phenotype with profound circulatory collapse.

Causes and Risk Factors

Underlying Mechanism

Exact cause is still under investigation, but prevailing theories include:

• Post‑infectious immune dysregulation: A delayed hyper‑inflammatory response triggered by viral antigens that persist in the gut or other reservoirs.
• Superantigen hypothesis: SARS‑CoV‑2 spike protein may act like a superantigen, causing massive T‑cell activation similar to toxic shock syndrome.
• Genetic susceptibility: Certain HLA types (e.g., HLA‑B*46) and innate immune gene variants appear over‑represented in MIS‑C cohorts.

Risk Factors

• Recent SARS‑CoV‑2 infection or exposure (confirmed by PCR or serology).
• Age 5‑12 years (peak), though cases are reported from infancy to late adolescence.
• Male sex (approximately 60 % of reported cases).
• Black, Hispanic, or South‑Asian ethnicity—higher incidence possibly reflecting social determinants of health and exposure risk.<sup>[3]</sup>
• Pre‑existing obesity, asthma, or other chronic inflammatory conditions may modestly increase risk.

Diagnosis

Diagnosing MIS‑C requires a high index of suspicion and a systematic approach.

Clinical Criteria (CDC definition)

1. Fever ≥38 °C for ≥24 h.
2. Laboratory evidence of inflammation (elevated CRP, ESR, ferritin, procalcitonin, D‑dimer, or IL‑6).
3. Involvement of ≥2 organ systems.
4. Evidence of current or recent SARS‑CoV‑2 infection (positive PCR, antigen, or serology) OR known exposure within the prior 4 weeks.
5. Exclusion of alternative plausible diagnoses (e.g., bacterial sepsis, toxic shock).

Key Laboratory Tests

• Complete blood count – often shows lymphopenia, neutrophilia, and thrombocytopenia early, followed by thrombocytosis.
• Inflammatory markers – CRP, ESR, ferritin, procalcitonin, IL‑6.
• Coagulation profile – elevated D‑dimer, fibrinogen, PT/PTT.
• Cardiac enzymes – troponin, NT‑proBNP (elevated in myocardial involvement).
• COVID‑19 testing – PCR (nasopharyngeal), rapid antigen, and SARS‑CoV‑2 IgG/IgM antibodies.

Imaging and Cardiac Evaluation

• Echocardiogram: First‑line to assess left‑ventricular function, coronary artery dimensions, pericardial effusion.
• Electrocardiogram (ECG): Looks for arrhythmias, ST‑segment changes.
• Chest X‑ray / CT: Evaluate for pulmonary infiltrates, pleural effusion.
• Abdominal ultrasound or CT: When severe abdominal pain or ileus is present.

Differential Diagnosis

Conditions that can mimic MIS‑C include Kawasaki disease, toxic shock syndrome, bacterial sepsis, macrophage activation syndrome, and acute COVID‑19 pneumonia. Careful history, lab trends, and imaging help distinguish them.<sup>[4]</sup>

Treatment Options

Management is multidisciplinary, involving pediatric intensivists, cardiologists, rheumatologists, and infectious disease specialists.

First‑Line Immunomodulation

• Intravenous Immunoglobulin (IVIG): 2 g/kg single infusion (most commonly used). Reduces fever and coronary inflammation in >80 % of patients.<sup>[5]</sup>
• Aspirin: High‑dose (30‑50 mg/kg/day) until afebrile, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect, similar to Kawasaki protocol.

Adjunctive Therapies

• Corticosteroids: Methylprednisolone 1‑2 mg/kg/day (IV) or pulse dosing (10‑30 mg/kg) for refractory cases.
• Biologic agents:
  • Anti‑IL‑6 receptor (tocilizumab) or anti‑IL‑1 (anakinra) for cytokine‑storm features.
  • Infliximab (anti‑TNF) when coronary artery dilatation persists despite IVIG.
• Anticoagulation: Low‑molecular‑weight heparin or enoxaparin if D‑dimer >5× ULN or documented thrombosis.

Supportive Care

• Fluid resuscitation and vasoactive agents (e.g., norepinephrine) for shock.
• Ventilatory support (high‑flow nasal cannula, CPAP, or mechanical ventilation) as needed.
• Renal replacement therapy for acute kidney injury.
• Monitoring in a pediatric intensive care unit (PICU) for at least 48‑72 h after stabilization.

Long‑Term Follow‑up

After discharge, children require:

• Serial echocardiograms (at 2 weeks, 6 weeks, and 3 months) to track coronary status.
• Cardiology or rheumatology clinic visits for medication tapering.
• Re‑evaluation of growth, exercise tolerance, and neurocognitive function.

Living with Kawasaki‑like Multisystem Inflammatory Syndrome in Children (MIS‑C)

Recovery can be swift, but families often need practical guidance to manage lingering effects.

• Activity restrictions: Limit vigorous exercise for 4‑6 weeks or until cardiac clearance is obtained.
• Medication adherence: Keep a daily log for aspirin and any steroid taper; set alarms.
• Nutrition: Small, frequent meals if appetite is reduced; ensure adequate protein for healing.
• Hydration: Encourage fluids; monitor urine output.
• School reintegration: Provide a physician’s note; start with a gradual schedule and allow rest periods.
• Emotional support: Children may experience anxiety or post‑traumatic stress; counseling or support groups (e.g., MIS‑C families networks) are beneficial.
• Vaccination: COVID‑19 vaccination is strongly recommended once the child has recovered (usually ≥90 days post‑illness) to lower risk of recurrence.<sup>[6]</sup>

Prevention

• COVID‑19 vaccination: Fully vaccinated children (including booster where eligible) have a markedly lower risk of MIS‑C.<sup>[6]</sup>
• Masking & ventilation: In high‑transmission settings, especially for unvaccinated or immunocompromised children.
• Prompt testing & isolation: Early identification of SARS‑CoV‑2 infection limits viral load and may blunt the subsequent hyper‑inflammatory response.
• Healthy lifestyle: Adequate sleep, balanced diet, regular physical activity, and control of obesity may reduce overall inflammatory burden.
• Public health measures: Community vaccination, contact tracing, and safe school policies help lower overall exposure.

Complications

If not recognized or inadequately treated, MIS‑C can lead to serious, sometimes permanent, sequelae:

• Cardiac: Coronary artery aneurysms or ectasia (up to 15 % in early reports, now <5 % with timely IVIG), myocardial dysfunction, arrhythmias, heart failure.
• Shock & organ failure: Persistent hypotension, multi‑organ dysfunction, need for extracorporeal membrane oxygenation (ECMO).
• Thromboembolism: Deep vein thrombosis, pulmonary embolism due to hypercoagulable state.
• Neurologic: Seizures, encephalopathy, stroke (rare).
• Renal: Acute kidney injury requiring dialysis.
• Long‑term sequelae: Potential for reduced exercise capacity, chronic hypertension, or persisting coronary changes.

When to Seek Emergency Care

```